Development goals
A differentiated target profile.
The STC platform is being developed toward a once-daily oral therapy with less dependence on food and a more predictable pharmacokinetic profile.
Once-daily
Designed for a convenient, once-daily dose.
Less food dependence
Designed to reduce the influence of food on absorption.
More predictable PK
Designed for more consistent testosterone exposure and levels.
Activated in the liver to release testosterone.
Testosterone taken by mouth is extensively broken down by the liver before it can reach circulation, which is why most oral formulations have struggled to deliver consistent, predictable exposure. That first-pass metabolism is the central obstacle STC-101 is designed to work with, not around.
STC-101 is an oral prodrug designed to activate in the liver and release testosterone, using the body's own metabolic machinery rather than working against it. The goal is a practical, once-daily therapy with more predictable exposure, built through a stepwise, data-driven process across computational, in vitro, and in vivo studies.
Preclinical proof-of-concept.
Preclinical work to date spans computational modeling, liver-cell studies, and animal pharmacokinetics, each testing a different part of how STC-101 is designed to work.
Molecular simulations
Strong binding to the liver enzymes involved in activation.
Liver-cell studies
Conversion evaluated across four species: mouse, rat, dog, and human.
Mouse studies
A prolonged window of elevated testosterone levels following administration.
These are development goals and non-clinical, preclinical findings. They have not been evaluated in humans and do not establish safety or efficacy.